Old Web
English
Sign In
Acemap
>
authorDetail
>
Peter Hillmen
Peter Hillmen
University of Leeds
Medicine
Immunology
Oncology
Internal medicine
Chronic lymphocytic leukemia
4
Papers
86
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Laboratory Diagnosis of Chronic Lymphocytic Leukaemia
2019
Andy C. Rawstron
Ruth M de Tute
Roger G. Owen
Peter Hillmen
Show All
Source
Cite
Save
Citations (0)
Updated Preliminary Results of a Phase 1b Dose Escalation and Dose Expansion Study of Tirabrutinib Alone or in Combination with Idelalisib or Entospletinib in Patients with Previously Treated Chronic Lymphocytic Leukemia
2018
Blood
Alexey V. Danilov
Charles Herbaux
Martin J. S. Dyer
Peter Hillmen
Simon Rule
Ebenezer A. Kio
Xi Huang
Siddhartha Mitra
Lionel Karlin
Christopher Fegan
Show All
Source
Cite
Save
Citations (1)
Ibrutinib and Obinutuzumab in CLL: Improved MRD Response Rates with Substantially Enhanced MRD Depletion for Patients with >1 Year Prior Ibrutinib Exposure
2018
Blood
Andy C. Rawstron
Talha Munir
Kristian Brock
Nichola Webster
Samuel Munoz Vicente
Francesca Yates
Sophie Cramp
Rebecca Bishop
Surita Dalal
Ruth M de Tute
Oonagh Sheehy
Andrew R Pettitt
Christopher P. Fox
Stephen Devereux
Christopher Fegan
Donald Macdonald
Adrian Bloor
Peter Hillmen
Show All
Source
Cite
Save
Citations (4)
Minimal residual disease is an independent predictor for 10-year survival in CLL
2016
Blood
Marwan Kwok
Andy C. Rawstron
Abraham M. Varghese
Paul Evans
Sheila J. M. O’Connor
Chi Doughty
Darren J. Newton
Paul Moreton
Peter Hillmen
Show All
Source
Cite
Save
Citations (81)
1